| Reaction Details |
|---|
 | Report a problem with these data |
| Target | RAF proto-oncogene serine/threonine-protein kinase |
|---|
| Ligand | BDBM16673 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_734960 (CHEMBL1693567) |
|---|
| IC50 | 6±n/a nM |
|---|
| Citation |  Gould, AE; Adams, R; Adhikari, S; Aertgeerts, K; Afroze, R; Blackburn, C; Calderwood, EF; Chau, R; Chouitar, J; Duffey, MO; England, DB; Farrer, C; Forsyth, N; Garcia, K; Gaulin, J; Greenspan, PD; Guo, R; Harrison, SJ; Huang, SC; Iartchouk, N; Janowick, D; Kim, MS; Kulkarni, B; Langston, SP; Liu, JX; Ma, LT; Menon, S; Mizutani, H; Paske, E; Renou, CC; Rezaei, M; Rowland, RS; Sintchak, MD; Smith, MD; Stroud, SG; Tregay, M; Tian, Y; Veiby, OP; Vos, TJ; Vyskocil, S; Williams, J; Xu, T; Yang, JJ; Yano, J; Zeng, H; Zhang, DM; Zhang, Q; Galvin, KM Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors. J Med Chem54:1836-46 (2011) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| RAF proto-oncogene serine/threonine-protein kinase |
|---|
| Name: | RAF proto-oncogene serine/threonine-protein kinase |
|---|
| Synonyms: | C-Raf Protein Kinase | Proto-oncogene c-RAF (RAF1) | RAF | RAF proto-oncogene
serine/threonine-protein kinase (C-Raf) | RAF1 | RAF1_HUMAN | Raf-1 | Serine/threonine-protein kinase
RAF | Serine/threonine-protein kinase C-Raf | cRaf |
|---|
| Type: | Serine/threonine-protein kinase |
|---|
| Mol. Mass.: | 73082.52 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P04049 |
|---|
| Residue: | 648 |
|---|
| Sequence: | MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRV
FLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAAS
LIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKV
PTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTF
NTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNL
SPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSF
GTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIV
TQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGL
TVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYE
LMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFP
QILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF
|
|
|
|---|
| BDBM16673 |
|---|
| n/a |
|---|
| Name | BDBM16673 |
|---|
| Synonyms: | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-picolinamide;tosylic acid | BAY 43-9006 | BAY 439006 | BAY439006 | CHEMBL1336 | Hit compound, 8 | Nexavar | Sorafenib | Sorafenib, 4 | US10183928, Sorafenib | US10202365, Compound Sorafenib | US10227329, Compound Sorafenib | US10584114, Compound Sorafenib | US10774070, Compound Sorafenib | US10980809, Example Sorafenib | US11279688, Compound Sorafenib | US11505527, Compound Sorafenib | US9029401, Sorafenib | US9469639, Sorafenib | US9902709, Comparative example 1 | Xarelto | cid_216239 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C21H16ClF3N4O3 |
|---|
| Mol. Mass. | 464.825 |
|---|
| SMILES | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 |
|---|
| Structure | 
|
|---|
Search and Browse
